Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025

Neurology · Published 2026-07-23 · DOI 10.1212/wnl.0000000000218373

Free full text

Authors (9)

Can Li, Mengyuan Fu, Karina Berg, Joshua Wallach, Kexin Ling, Ran Wei, Luwen Shi, Joseph Ross, Xiaodong Guan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Li, C., Fu, M., Berg, K., et al. (2026). Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025. Neurology. https://doi.org/10.1212/wnl.0000000000218373

Related articles

• Clinical Trial Outcomes in the Alzheimer's Disease Spectrum · Neurology · 2026 · Cites or is cited by this article · Same journal
• Alzheimer's disease drug development pipeline: 2026 · Alzheimer’s & Dementia: Translational Research & Clinical Interventions · 2025 · Cites or is cited by this article
• Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy · Neurology · 2026 · Same journal
• Convulsions, Palsy, and the Spanish Inquisition · Neurology · 2026 · Same journal
• Natural History of Adult-Onset Myotonic Dystrophy Type 1 · Neurology · 2026 · Same journal
• Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis · Neurology · 2026 · Same journal
• Child Neurology: Early-Onset, Rapidly Progressive, and Refractory DYT- TOR1A Status Dystonicus · Neurology · 2026 · Same journal
• Teaching NeuroImage: Utility of Arterial Spin Labeling in Detecting Occult Micro-AVM in Angiogram-Negative Acute ICH · Neurology · 2026 · Same journal
• Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD · Neurology · 2026 · Same journal
• Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes · Neurology · 2026 · Same journal